BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 19501879)

  • 1. External validation of an international multicenter study to predict survival in Korean patients with pT2N0M0 renal cell carcinoma.
    Ku JH; Moon KC; Kwak C; Kim HH
    Urology; 2009 Aug; 74(2):359-63. PubMed ID: 19501879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.
    Klatte T; Patard JJ; Goel RH; Kleid MD; Guille F; Lobel B; Abbou CC; De La Taille A; Tostain J; Cindolo L; Altieri V; Ficarra V; Artibani W; Prayer-Galetti T; Allhoff EP; Schips L; Zigeuner R; Figlin RA; Kabbinavar FF; Pantuck AJ; Belldegrun AS; Lam JS
    J Urol; 2007 Jul; 178(1):35-40; discussion 40. PubMed ID: 17521678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of tumor size on long-term survival of patients with organ-confined renal cell cancer].
    Merseburger AS; Wegener G; Horstmann M; Oelke M; Zumbrägel A; Bokemeyer C; Kollmannsberger C; Jonas U; Stenzl A; Kuczyk M
    Aktuelle Urol; 2003 Dec; 34(7):469-74. PubMed ID: 14655083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
    Yoo C; Song C; Hong JH; Kim CS; Ahn H
    J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a postoperative prognostic model consisting of tumor microvascular invasion, size, and grade to predict disease-free and cancer-specific survival of patients with surgically resected renal cell carcinoma.
    May M; Brookman-Amissah S; Kendel F; Knoll N; Roigas J; Hoschke B; Miller K; Gilfrich C; Pflanz S; Gralla O
    Int J Urol; 2009 Jul; 16(7):616-21. PubMed ID: 19456988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma.
    Brookman-Amissah S; Kendel F; Spivak I; Pflanz S; Roigas J; Klotz T; May M
    BJU Int; 2009 May; 103(10):1375-80. PubMed ID: 19040527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reassessment of the 1997 TNM classification system for renal cell carcinoma.
    Elmore JM; Kadesky KT; Koeneman KS; Sagalowsky AI
    Cancer; 2003 Dec; 98(11):2329-34. PubMed ID: 14635066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
    Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
    Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metachronous metastatic potential of small renal cell carcinoma: dependence on tumor size.
    Ku JH; Moon KC; Kwak C; Kim HH
    Urology; 2009 Dec; 74(6):1271-5. PubMed ID: 19616288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era.
    Clark PE; Veys JA; Eskridge MR; Woodruff RD; Hall MC
    Urol Oncol; 2005; 23(5):328-32. PubMed ID: 16144666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes following partial nephrectomy by tumor size.
    Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
    J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of TNM, 2002 version, in localized renal cell carcinoma: is it able to predict different cancer-specific survival probability?
    Ficarra V; Novara G; Galfano A; Novella G; Schiavone D; Artibani W
    Urology; 2004 Jun; 63(6):1050-4. PubMed ID: 15183948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma.
    Katz MD; Serrano MF; Grubb RL; Skolarus TA; Gao F; Humphrey PA; Kibel AS
    J Urol; 2010 Mar; 183(3):909-14. PubMed ID: 20083280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.
    Komai Y; Saito K; Sakai K; Morimoto S
    BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.